
GLP-3RT
Triple agonist research peptide (GLP-1 / GIP / glucagon) studied for metabolic and body-composition endpoints.

Dual GIP/GLP-1 receptor agonist researched for glucose regulation and weight-related endpoints.
This lot has sold through. Tirzepatide remains part of our permanent catalog and returns as soon as the next independently tested lot clears HPLC verification. Message us on Telegram or use the contact form and we'll let you know the day it's back in stock — or reserve one from the incoming lot.
"Packed clean and they kept me in the loop the whole time."
"Third order. Same every time, which is exactly why I keep coming back."
"Good overall. I'd pay a few bucks extra for a faster shipping option if they added one."
"Good first impression start to finish. Nothing felt half done."
"Had a question about strengths before ordering and got a helpful answer in a few hours."
"Smooth from start to finish. The shipping notifications actually came when they were supposed to."
"Easy site and no surprise fees at the last step. That alone earns points from me."
"Processed fast and got here safe. That's really it."
"Vial and label matched the photos exactly. That's not always the case."
"Quick checkout, quick shipping, showed up exactly like I expected."
"Site was easy to use. Only reason it's not a five is the package sat an extra day in transit."
"Second order and it went just as smoothly as the first one."
Tirzepatide is a dual GIP/GLP-1 receptor agonist widely used as a reference compound in metabolic research examining incretin receptor co-activation and its downstream effects on glucose-regulatory signaling pathways.
Laboratories use tirzepatide in comparative binding-affinity assays and cell-based signaling studies alongside single-target incretin agonists to characterize differential receptor activation profiles.
Each shipped lot is verified through independent third-party analytical testing, with a Certificate of Analysis published on our COA page.
| Form | Lyophilized powder |
|---|---|
| Quantity per vial | 15mg |
| Appearance | White lyophilized powder |
| SKU | NSL-TIRZ-15 |
Each lot undergoes independent third-party HPLC/MS analysis. The current lot's COA is published on our COA page.
Learn more about our sourcing and testing process on our Testing & Quality page. View the current lot's Certificate of Analysis.
Tirzepatide is a synthetic dual agonist at the GIP and GLP-1 receptors, characterized across the SURPASS and SURMOUNT clinical trial programs. Approved prescription products exist; research-grade material supplied for laboratory work is a separate, unapproved category.
Read the Tirzepatide research overviewFree U.S. shipping on orders over $200; otherwise a flat $9.99 shipping rate applies. All sales are final. See our full Shipping & Returns policy for details.
It is studied as a dual agonist engaging both GIP and GLP-1 receptor pathways.
Yes, view it on our COA page.
A single 15mg vial size is currently offered.

Triple agonist research peptide (GLP-1 / GIP / glucagon) studied for metabolic and body-composition endpoints.

Mitochondrial-derived research peptide studied for metabolic and cellular energy endpoints.
All products sold by North Summit Labs are intended strictly for in-vitro laboratory research and are not for human or animal consumption.